Semaglutide treatment of antipsychotic-treated patients with schizophrenia, prediabetes, and obesity: the HISTORI randomized clinical trial
Ganeshalingam AA, Uhrenholt N, Arnfred S, et al.
JAMA Psychiatry. Pub. online 3 Sep 2025.
Leggi
Breaking news
Clinical features modifying the cardiovascular benefits of GLP-1 receptor agonists: a systematic review and meta-analysis
Kalayci A, Januzzi JL, Mitsunami M, et al.
Eur Heart J Cardiovasc Pharmacother. Pub. online 31 Aug 2025.
Leggi
FDA launches green list to protect americans from illegal imported GLP-1 drug ingredients
5 settembre 2025
Leggi
FDA’s concerns with unapproved GLP-1 drugs used for weight loss
5 settembre 2025
Leggi
EMA: warning about sharp rise in illegal medicines sold in the EU
3 settembre 2025
Leggi
AIFA: allerta sull’aumento di farmaci illegali venduti nell’UE come agonisti del recettore del GLP-1
4 settembre 2025
Leggi
AIFA: nota Informativa Importante su Victoza: rischio di carenza a causa della cessazione della commercializzazione (interruzione)
5 settembre 2025
Leggi
AIFA: modifiche monitoraggio LEQVIO e passaggio a PIANO TERAPEUTICO WEB-BASED
4 settembre 2025
Leggi
The selection and use of essential medicines, 2025: report of the 25th WHO Expert Committee on Selection and Use of Essential Medicines, executive summary.
5 settembre 2025
Leggi
Advancing type 1 diabetes management: integrating novel therapies, technologies, and adjunctive approaches
Snaith JR, Narongkiatikhun P, Bjornstad P, et al.
Diabetes Care. Pub. online 29 Aug 2025.
Leggi